Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Pegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic patients. This study evaluated the efficacy and tolerability of peginterferon and ribavirin treatment in patients with hepatitis C virus (HCV)-related cirrhosis. Methods: Eighty-six patients with clinically diagnosed liver cirrhosis were treated with either peginterferon alpha-2a (n=51) or peginterferon alpha-2b (n=35) plus ribavirin. The sustained virologic response (SVR) and adverse effects were analyzed retrospectively. Results: Of the 86 patients (55 males), 48 patients (55.8%) had HCV genotype 1 infection and 38(44.2%) had genotype non-1 infection. The overall SVR rate was 34.9% (30/86), and the rates of SVR in the genotype 1 and non-1 patients were 20.8% (10/48) and 52.6% (20/38), respectively. The multivariate analysis revealed that having HCV genotype 1 (P=0.003) and high baseline viral load (>8.0×105 IU/mL, P=0.012) were the independent predictive factors for SVR failure. In 20.9% (18/86) of the patients, treatment was not completed due to adverse events (27.8%), loss to follow-up (50.0%),and other reasons (22.2%). Conclusions: Peginterferon and ribavirin combination therapy was relatively effective and feasible for clinically diagnosed HCV patients, especially in those with genotype non-1 infection and low baseline viral load.
Abstract
Background/Aims: Pegylated interferon (peginterferon) and ribavirin combination therapy is less effective and associated with a higher frequency of serious complications in chronic hepatitis C patients with cirrhosis than in noncirrhotic patients. This study evaluated the efficacy and tolerability of peginterferon and ribavirin treatment in patients with hepatitis C virus (HCV)-related cirrhosis. Methods: Eighty-six patients with clinically diagnosed liver cirrhosis were treated with either peginterferon alpha-2a (n=51) or peginterferon alpha-2b (n=35) plus ribavirin. The sustained virologic response (SVR) and adverse effects were analyzed retrospectively. Results: Of the 86 patients (55 males), 48 patients (55.8%) had HCV genotype 1 infection and 38(44.2%) had genotype non-1 infection. The overall SVR rate was 34.9% (30/86), and the rates of SVR in the genotype 1 and non-1 patients were 20.8% (10/48) and 52.6% (20/38), respectively. The multivariate analysis revealed that having HCV genotype 1 (P=0.003) and high baseline viral load (>8.0×105 IU/mL, P=0.012) were the independent predictive factors for SVR failure. In 20.9% (18/86) of the patients, treatment was not completed due to adverse events (27.8%), loss to follow-up (50.0%),and other reasons (22.2%). Conclusions: Peginterferon and ribavirin combination therapy was relatively effective and feasible for clinically diagnosed HCV patients, especially in those with genotype non-1 infection and low baseline viral load.
참고문헌 (19)
- "Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium", J Viral Hepat, 6, pp.35~47 (1999)
- Shin HR, "Epidemiology of hepatitis C virus in Korea", Intervirology, 49, pp.18~22 (2006)
- Lauer GM, "Hepatitis C virus infection", N Engl J Med, 345, pp.41~52 (2001)
- Poynard T, "Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C", Hepatology, 32, pp.1131~1137 (2000)
- Shiratori Y, "Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival", Ann Intern Med, 142, pp.105~114 (2005)
- Strader DB, "American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C", Hepatology, 39, pp.1147~1171 (2004)
- Fried MW, "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection", N Engl J Med, 347, pp.975~982 (2002)
- Manns MP, "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial", Lancet, 358, pp.958~965 (2001)
- Braks RE, "Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin", World J Gastroenterol, 13, pp.5648~5653 (2007)
- Goyal N, "Non-invasive evaluation of liver cirrhosis using ultrasound", Clin Radiol, 64, pp.1056~1066 (2009)
- Colli A, "Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases", Radiology, 227, pp.89~94 (2003)
- Bruno S, "Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis", Hepatology, 51, pp.388~397 (2010)
- Di Marco V, "Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial", J Hepatol, 47, pp.484~491 (2007)
- Giannini EG, "Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension", J Intern Med, 266, pp.537~546 (2009)
- Syed E, "Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis", Scand J Gastroenterol, 43, pp.1378~1386 (2008)
- 윤현아, "만성 C형간염에서 페그인터페론과 리바비린 병합요법의 효과", Clinical and Molecular Hepatology, 14(1), pp.36~45 (2008), 대한간학회
- 김정일, "대전과 충청남북도에 거주하는 만성 C형간염 환자에서 페그인터페론 알파 2a와 2b의 초치료 효과 비교", Clinical and Molecular Hepatology, 14(4), pp.493~502 (2008), 대한간학회
- Furusyo N, "Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia", Dig Dis Sci, 47, pp.535~542 (2002)
- Xie Y, "Predictive factors for sustained response to interferon treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial", Hepatobiliary Pancreat Dis Int, 4, pp.213~219 (2005)